PF-Atlas › Clinical Trials › NCT01170065
Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis
BIBF 1120 · Phase 2
Registry ID
NCT01170065
Phase
Phase 2
Status
Completed
Drug / intervention
BIBF 1120
Sponsor
Boehringer Ingelheim
Start
2010-06-25
Enrollment
198
Locations
57
About this trial
The aim of this trial is to offer continuation of BIBF 1120 treatment for patients with Idiopathic Pulmonary Fibrosis (IPF) who have completed a prior clinical trial with that drug. The primary objective will be to establish the long term tolerability and safety profile of BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF). As a secondary objective the effects of long term treatment with BIBF 1120 on survival as well as safety and efficacy parameters will be investigated in an open-label, not randomized, un-controlled design.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT01170065 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.